,subjsummary,subj,rel,obj,objsummary,ref
0,ssris,selective serotonin reuptake inhibitors (ssris),first-line treatment,major depressive disorder (mdd),mdd,"in december 1987, a series of clinical studies confirmed that an ssri called fluoxetine was as effective as tcas for treating depression while causing fewer adverse effects. therefore, most guidelines currently recommend ssris as the first-line treatment for patients with major depression."
1,ect,electroconvulsive therapy (ect),most effective,major depressive disorder (mdd),mdd,"ect is arguably the most effective treatment modality in psychiatry, and its superiority over pharmacotherapy for major unipolar depression is widely supported."
2,maois,monoamine oxidase inhibitors (maois),less commonly used,major depressive disorder (mdd),mdd,"due to their irreversible inhibition of monoamine oxidase, maois have numerous side effects such as hepatotoxicity and hypertensive crisis, that can lead to lethal intracranial hemorrhage. consequently, maois have become less commonly used over time."
3,cbt,cognitive behavioral therapy (cbt),first-line treatment,major depressive disorder (mdd),mdd,"based on robust evidence, cbt is one of the most well-documented and validated psychotherapeutic methods available. it has been recommended in most guidelines as a first-line treatment."
4,ketamine,ketamine,highly effective,treatment-resistant depression,trd,"intravenous sub-anesthetic doses of ketamine have a very quick effect on resistant unipolar (and, possibly, bipolar) depression and acute suicidal ideation. the antidepressant effect of ketamine can persist for several days but eventually wane."
5,rtms,repetitive transcranial magnetic stimulation (rtms),widely used,research on depression,depression research,"this method, which is a type of biological stimulation that affects brain metabolism and neuronal electrical activity, has been widely used in research on depression."
6,exercise,physical exercise,recommended,major depressive disorder (mdd),mdd,"most guidelines for treating depression, include the national institute for health and care excellence, the american psychiatric association, and the royal australian and new zealand college of psychiatrists, recommend that depressed patients perform regular physical activity to alleviate symptoms and prevent relapse."
7,ssris,selective serotonin reuptake inhibitors (ssris),symptom,nausea and loss of appetite,nausea & appetite loss,"currently available ssris include fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, and escitalopram. they have elicited different tolerance rates and side effects - mostly sexual and digestive (nausea and loss of appetite), as well as irritability, anxiety, insomnia, and headache."
0,mdd,major depressive disorder,definition,"a mental health condition characterized by persistent feelings of sadness, emptiness, or hopelessness",psychological condition,"""which compare any of the follow antidepressant at therapeutic dose range for the acute treatment of unipolar major depression in adult"""
1,mdd,major depressive disorder,associated with,"persistent feelings of sadness, emptiness, or hopelessness",symptoms,"""which compare any of the follow antidepressant at therapeutic dose range for the acute treatment of unipolar major depression in adult"""
2,antidepressants,antidepressants,definition,medication used for the treatment of major depressive disorder,medication,"""which compare any of the follow antidepressant at therapeutic dose range for the acute treatment of unipolar major depression in adult"""
3,"mirtazapine, escitalopram, venlafaxine, sertraline","mirtazapine, escitalopram, venlafaxine, sertraline",more effective,"duloxetine, fluoxetine, fluvoxamine, paroxetine, reboxetine",compared antidepressants,"""mirtazapine, escitalopram, venlafaxine, and sertraline be significantly more efficacious"""
4,escitalopram and sertraline,escitalopram and sertraline,benefits,better profile of acceptability leading to significantly fewer discontinuations,acceptability,"""escitalopram and sertraline show the good profile of acceptability"""
5,"mirtazapine, escitalopram, venlafaxine, sertraline","mirtazapine, escitalopram, venlafaxine, sertraline",highly effective,major depression,treatment effectiveness,"""mirtazapine, escitalopram, venlafaxine, and sertraline be significantly more efficacious"""
6,reboxetine,reboxetine,less effective,all other tested antidepressants,in comparison,"""reboxetine be significantly less efficacious than all the other antidepressant tested"""
7,reboxetine,reboxetine,not effective,routine first-line acute treatment for major depression,treatment option,"""therefore, reboxetine should not be used as a routine first-line acute treatment for major depression"""
8,sertraline,sertraline,more commonly used,moderate to severe major depression,treatment choice,"""sertraline might be the best choice when starting treatment for moderate to severe major depression in adults because it has the most favourable balance between benefits, acceptability, and acquisition cost"""
0,anxious depression,anxious depression,definition,major depressive disorder with high levels of anxiety symptoms,mdd w/ high anxiety,"""definition of anxious depression as in our previous study (6,9), anxious depression be define as major depressive disorder with high level of anxiety symptom"""
1,nonanxious depression,nonanxious depression,definition,major depressive disorder without high levels of anxiety symptoms,mdd w/o high anxiety,implied definition from the context of discussing anxious depression
2,anxious depression,anxious depression,more common than,nonanxious depression,nonanxious depression,"""anxious depression be significantly more common than nonanxious depression among african americans than in other racial/ethnic group; among hispanic than non-hispanic; among those see in primary care setting than those in psychiatric care setting; among those who be unemployed than those who be employ; among those who be marrie, divorced, or widow than among those who had never marry; and among those with less education, those with public insurance, and those with less income."""
3,citalopram,citalopram,first-line treatment,anxious depression in star*d level 1,ad in star*d l1,"""in level 1 of star*d, 53.2% of patient have anxious depression. remission be significantly less likely and take long to occur in these patient than in those with nonanxious depression"""
4,anxious depression,anxious depression,associated with,poor acute outcome following antidepressant treatment,poor outcome after ad treatment,"""conclusion: anxious depression be associate with poor acute outcome than nonanxious depression follow antidepressant treatment."""
5,anxious and nonanxious depression,anxious and nonanxious depression,treatment options,"switch to sustain-release bupropion, sertraline, or extend-release venlafaxine or augmentation with sustain-release bupropion or buspirone",switch/augmentation options,"""in level 2, a total of 1,292 patient who do not remit with or tolerate citalopram be randomly assign either to switch to sustain-release bupropion (n=239), sertraline (n=238), or extend-release venlafaxine (n=250) or to continue take citalopram and receive augmentation with sustain-release bupropion (n=279) or buspirone (n=286)"""
6,star*d level 2,star*d level 2,overview,adult outpatients with major depressive disorder not remitting after citalopram in level 1 were assigned different treatment pathways,non-remitters to citalopram treatment pathways,"""in level 2 of star*d, 1,292 adult outpatient with major depressive disorder who have no remission of symptom in level 1 or could not tolerate citalopram (in the case of the switch option only) be randomly assign either to switch (overall n=727) to sustain-release bupropion (at a maximal daily dose of 400 mg; n=239), sertraline (at a maximal daily dose of 200 mg; n=238), or extend-release venlafaxine (at a maximal daily dose of 375 mg; n=250) or to continue take citalopram and receive augmentation (overall n=565) with sustain-release bupropion (at a dose of up to 400 mg per day; n=279) or buspirone (at a dose of up to 60 mg per day; n=286)"""
7,anxious depression,anxious depression,symptom,"functional impairment, greater illness chronicity, increased risk of suicidality",functional impairment & suicide risk,"""in patient with high level of anxiety accompanying major depression, greater severity of depressive illness and functional impairment, greater illness chronicity, and an increase risk of suicidality have been report"""
